1. World Health Organization (WHO). Global Tuberculosis
Report 2018. WHO; 2018.
2. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM,
Roberts DA, et al. Global, regional, and national incidence
and mortality for HIV, tuberculosis, and malaria during 1990-
2013: a systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 2014;384(9947):1005-70. doi: 10.1016/
s0140-6736(14)60844-8.
3. Altice FL, Kamarulzaman A, Soriano VV, Schechter M,
Friedland GH. Treatment of medical, psychiatric, and
substance-use comorbidities in people infected with HIV who
use drugs. Lancet. 2010;376(9738):367-87. doi: 10.1016/
s0140-6736(10)60829-x.
4. World Health Organization (WHO). Integrating Collaborative
TB and HIV Services within a Comprehensive Package of
Care for People Who Inject Drugs: Consolidated Guidelines.
WHO; 2016.
5. Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A,
Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit drug
use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health
Survey. Addiction. 2016;111(10):1836-47. doi: 10.1111/
add.13453.
6. Moradinazar M, Najafi F, Jalilian F, Pasdar Y, Hamzeh B,
Shakiba E, et al. Prevalence of drug use, alcohol consumption,
cigarette smoking and measure of socioeconomic-related
inequalities of drug use among Iranian people: findings from a
national survey. Subst Abuse Treat Prev Policy. 2020;15(1):39.
doi: 10.1186/s13011-020-00279-1.
7. Shadloo B, Amin-Esmaeili M, Haft-Baradaran M, Noroozi
A, Ghorban-Jahromi R, Rahimi-Movaghar A. Use of
amphetamine-type stimulants in the Islamic Republic of Iran,
2004-2015: a review. East Mediterr Health J. 2017;23(3):245-
56. doi: 10.26719/2017.23.3.245.
8. Akbari H, Roshanpajouh M, Nourijelyani K, Mansournia MA,
Rahimi-Movaghar A, Yazdani K. Profile of drug users in the
residential treatment centers of Tehran, Iran. Health Promot
Perspect. 2019;9(3):248-54. doi: 10.15171/hpp.2019.34.
9. Noroozi A, Malekinejad M, Rahimi-Movaghar A. Factors
influencing transition to Shisheh (methamphetamine)
among young people who use drugs in Tehran: a qualitative
study. J Psychoactive Drugs. 2018;50(3):214-23. doi:
10.1080/02791072.2018.1425808.
10. Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar
A, Amin-Esmaeili M, Noroozi A. High hepatitis C virus
prevalence among drug users in Iran: systematic review and
meta-analysis of epidemiological evidence (2001-2012). Int J
Infect Dis. 2015;40:116-30. doi: 10.1016/j.ijid.2015.09.022.
11. Rahimi J, Gholami J, Amin-Esmaeili M, Fotouhi A,
Rafiemanesh H, Shadloo B, et al. HIV prevalence among
people who inject drugs (PWID) and related factors in
Iran: a systematic review, meta-analysis and trend analysis.
Addiction. 2020;115(4):605-22. doi: 10.1111/add.14853.
12. Rahimi-Movaghar A, Amin-Esmaeili M, Haghdoost AA,
Sadeghirad B, Mohraz M. HIV prevalence amongst
injecting drug users in Iran: a systematic review of studies
conducted during the decade 1998-2007. Int J Drug Policy.
2012;23(4):271-8. doi: 10.1016/j.drugpo.2011.09.002.
13. Amin-Esmaeili M, Rahimi-Movaghar A, Haghdoost
AA, Mohraz M. Evidence of HIV epidemics among
non-injecting drug users in Iran: a systematic review.
Addiction. 2012;107(11):1929-38. doi: 10.1111/j.1360-
0443.2012.03926.x.
14. Melese A, Demelash H. The prevalence of tuberculosis among
prisoners in Ethiopia: a systematic review and meta-analysis
of published studies. Arch Public Health. 2017;75:37. doi:
10.1186/s13690-017-0204-x.
15. Dianatinasab M, Joulaei H, Ghorbani M, Zarei N, Rezaeian S,
Fararouei M, et al. Prevalence of tuberculosis in HIV-positive
prisoners: a systematic review and meta-analysis. AIDS Rev.
2018;20(2):114-24. doi: 10.24875/AIDSRev.M18000023.
16. Edge CL, King EJ, Dolan K, McKee M. Prisoners co-infected
with tuberculosis and HIV: a systematic review. J Int AIDS
Soc. 2016;19(1):20960. doi: 10.7448/ias.19.1.20960.
17. Kawatsu L, Uchimura K, Izumi K, Ohkado A. [A systematic
review on the prevalence and incidence of latent
tuberculosis infection among prison population]. Kekkaku.
2016;91(4):457-64. [Japanese].
18. Simou E, Britton J, Leonardi-Bee J. Alcohol consumption and
risk of tuberculosis: a systematic review and meta-analysis.
Int J Tuberc Lung Dis. 2018;22(11):1277-85. doi: 10.5588/
ijtld.18.0092.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche
PC, Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration.
J Clin Epidemiol. 2009;62(10):e1-34. doi: 10.1016/j.
jclinepi.2009.06.006.
20. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi
G, Rapi S, et al. Panethnic differences in blood pressure in
Europe: a systematic review and meta-analysis. PLoS One.
2016;11(1):e0147601. doi: 10.1371/journal.pone.0147601.
21. Bekfani T, Schöbel C, Pietrock C, Valentova M, Ebner N,
Döhner W, et al. Heart failure and sleep-disordered breathing:
susceptibility to reduced muscle strength and preclinical
congestion (SICA-HF cohort). ESC Heart Fail. 2020;7(5):2063-
70. doi: 10.1002/ehf2.12798.
22. Cochrane. Identifying and Measuring Heterogeneity. Available
from: https://handbook-5-1.cochrane.org/chapter_9/9_5_2_
identifying_and_measuring_heterogeneity.htm.
23. Mamani M, Majzoobi MM, Torabian S, Mihan R, Alizadeh
K. Latent and active tuberculosis: evaluation of injecting
drug users. Iran Red Crescent Med J. 2013;15(9):775-9. doi:
10.5812/ircmj.6283.
24. Tavanaee Sani A, Khaleghi Nia M. Epidemiologic evaluation
and some species in injection drug users that admitted in
infectious department of Imam Reza hospital [2007-2009]. J
Iran Med Council. 2012;30(2):155-61. [Persian].
25. Nazer MR, Vaziri S, Janbakhsh A. The prevalence of
smears positive pulmonary tuberculosis in a prison. Yafteh.
2015;17(1):15-27. [Persian].
26. Asadi S, Marjani M. Epidemiological study and prevalence of
various infectious diseases in injecting drug users Hospitalized
in Infectious Diseases Department of Shahid Beheshti
University of Medical Sciences in 2002-2003. Iranian Journal
of Infectious Diseases and Tropical Medicine. 2004; 25 (9):
53-61. [Persian].
27. Sharifi-Mood B, Metanat M. Infection among hospitalized
injection drug users. J Med Sci. 2006;6(4):686-9.
28. Sarvghad M, Naderi HR, Farokhnia M, Bojdi A.
Epidemiological study of injecting drug users haspitalized to
the infectious ward of Imam Reza hospital in Mashhad. Med J
Mashhad Univ Med Sci. 2005;48(87):79-84. [Persian].
29. Honarvar B, Bagheri Lankarani K, Odoomi N, Roudgari A,
Moghadami M, Afsar Kazerooni P, et al. Pulmonary and latent
tuberculosis screening in opiate drug users: an essential and
neglected approach for harm-reduction facilities. J Addict Med.
2013;7(4):230-5. doi: 10.1097/ADM.0b013e31828d05ab.
30. Askarian M, Karmi A, Sadeghi-Hassanabadi A. Tuberculosis
among never-jailed drug abusers. East Mediterr Health J.
2001;7(3):461-4.
31. Sadeghi Hassanabadi A, Yaghout M. Tuberculosis among
drug addicts in Shiraz, Islamic Republic of Iran. East Mediterr
Health J. 1998;4(3):567-70.
32. Sabermahani A, Barouni M, Seyedin H, Aryankhesal A.
Provincial human development index, a guide for efficiency
level analysis: the case of Iran. Iran J Public Health.
2013;42(2):149-57.
33. Tavakoli A. Incidence and prevalence of tuberculosis in
Iran and neighboring countries. Zahedan J Res Med Sci.
2017;19(7):e9238. doi: 10.5812/zjrms.9238.
34. Pourhossein B, Doosti Irani A, Mostafavi E. Major infectious
diseases affecting the Afghan immigrant population of Iran:
a systematic review and meta-analysis. Epidemiol Health.
2015;37:e2015002. doi: 10.4178/epih/e2015002.
35. Motamedizadeh F, Alimohammadzadeh K, Hosseini SM.
Monitoring and evaluation of program performance and
management control system of tuberculosis: a ten-year crosssectional study in Sistan and Baluchestan province, Iran.
Shiraz E Med J. 2018;19(9):e60497. doi: 10.5812/semj.60497.
36. Grenfell P, Baptista Leite R, Garfein R, de Lussigny S,
Platt L, Rhodes T. Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature. Drug
Alcohol Depend. 2013;129(3):180-209. doi: 10.1016/j.
drugalcdep.2012.11.013.
37. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit
drug use: review and update. Clin Infect Dis. 2009;48(1):72-
82. doi: 10.1086/594126.
38. Amin-Esmaeili M, Rahimi-Movaghar A, Gholamrezaei M,
Mohammad Razaghi E. Profile of people who inject drugs in
Tehran, Iran. Acta Med Iran. 2016;54(12):793-805.
39. Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel
N, Dolan K, et al. Prevention of transmission of HIV, hepatitis
B virus, hepatitis C virus, and tuberculosis in prisoners.
Lancet. 2016;388(10049):1115-26. doi: 10.1016/s0140-
6736(16)30769-3.
40. Mathur ML, Chaudhary RC. Increased risk of tuberculosis in
opium addicts. Indian J Med Sci. 1996;50(10):365-7.
41. Ghafour I, Hessami A, Naghibi SA, Hosseini SH, Moosazadeh
M. Profile of cigarette and drug use status in population of
Tabari cohort study. Addict Health. 2022;14(3):185-91. doi:
10.34172/ahj.2022.1240.
42. Abshenas-Jami M, Baneshi M, Nasirian M. Population size
estimation of drug users in Isfahan city (Iran) using network
scale-up method in 2018. Addict Health. 2021;13(4):249-58.
doi: 10.22122/ahj.v13i4.1238.
43. Rabirad N, Mohammad Nejad E, Hadizadeh MR, Begjan
J, Ehsani SR. The prevalence of TB in HIV patients and risk
factor with frequent referral (Iran, 2009-10). Iran Red Crescent
Med J. 2013;15(1):58-61. doi: 10.5812/ircmj.4401.
44. Alavi SM, Nadimi M, Shokri S, Zamani G. Latent tuberculosis
infection in individuals with human immunodeficiency virus
infection: comparison of tuberculin skin test to the anti TBIgM antibodies. Pak J Med Sci. 2010;26(1):11-4.
45. Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M.
Tuberculosis and HIV in people who inject drugs: evidence
for action for tuberculosis, HIV, prison and harm reduction
services. Curr Opin HIV AIDS. 2012;7(4):345-53. doi:
10.1097/COH.0b013e328354bd44.
46. Schluger NW, El-Bassel N, Hermosilla S, Terlikbayeva A,
Darisheva M, Aifah A, et al. Tuberculosis, drug use and HIV
infection in Central Asia: an urgent need for attention. Drug
Alcohol Depend. 2013;132 Suppl 1:S32-6. doi: 10.1016/j.
drugalcdep.2013.07.012.
47. Parhizgari N, Gouya MM, Mostafavi E. Emerging and reemerging infectious diseases in Iran. Iran J Microbiol.
2017;9(3):122-42.
48. Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani
OM, Ahmadnia S, et al. Iran in transition. Lancet.
2019;393(10184):1984-2005. doi: 10.1016/s0140-
6736(18)33197-0.
49. Azizi MH, Bahadori M. A brief history of tuberculosis in
Iran during the 19th and 20th centuries. Arch Iran Med.
2011;14(3):215-9.
)